Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18307681 | 1.00 | CNR2 (0.32) | CNR2PDF | |
| SCHEMBL19174544 | 1.00 | CNR2 (0.32) | CNR2PDF | |
| SCHEMBL18771454 | 0.94 | — | — | |
| SCHEMBL20629842 | 0.94 | — | — | |
| SCHEMBL2173087 | 0.93 | CNR2 (0.31) | CNR2 | |
| SCHEMBL16853951 | 0.93 | CNR2 (0.31) | CNR2 | |
| SCHEMBL3311795 | 0.93 | CNR2 (0.31) | CNR2 | |
| SCHEMBL7945603 | 0.93 | CNR2 (0.31) | CNR2 | |
| SCHEMBL19447840 | 0.91 | ALDH1A1 (0.32) | CNR2 | |
| SCHEMBL18721747 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3087085-B1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3159345-B1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3159345-A1 | INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| EP-2870160-B1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9440991-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015100145-A1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | CNR2 4655/4885PDF 444/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CNR2 3291/4885PDF 3073/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CNR2 2867/4885PDF 3021/4885 |
| US-10030033-B2 | Synthesis of an antiviral compound | EIF2AK2, MAVS, SARS1 | CNR2 4655/4885PDF 444/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CNR2 2867/4885PDF 3021/4885 |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | CNR2 4655/4885PDF 444/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | CNR2 2867/4885PDF 3021/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CNR2 2867/4885PDF 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.